Assess cardiac arrest risk during myeloma treatment.
The MICA score estimates cardiac risk in patients receiving proteasome inhibitor (PI) and immunomodulatory (IMiD) combination therapy for multiple myeloma. Risk factors include age ≥ 65, renal impairment, pre-existing cardiac disease, prolonged QTc, and use of PI+IMiD combinations. Higher scores warrant closer cardiac monitoring and possible dose adjustments.